Recent filings

Quarterly report [Sections 13 or 15(d)] - Nov. 17, 2023

Quarterly report [Sections 13 or 15(d)] - Nov. 17, 2023

Caribou Biosciences Reports Third Quarter 2023 Financial Results And Provides Business Update - Nov. 7, 2023

Caribou Biosciences, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareTh... - Nov. 7, 2023

Caribou Biosciences Announces Fda Clearance Of Ind Application For Cb-012, An Allogeneic Anti-Cll-1 Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia - Oct. 18, 2023

Termination of Material Definitive - Sept. 26, 2023

Caribou Biosciences, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareTh... - Aug. 8, 2023

Caribou Biosciences Reports Second Quarter 2023 Financial Results And Provides Business Update - Aug. 8, 2023

Steven A. Cohen just provided an update on share ownership of Caribou Biosciences, Inc. - July 20, 2023

Caribou Biosciences Announces Proposed Public Offering Of Common Stock - July 17, 2023

Caribou Biosciences, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - July 14, 2023

On July - July 14, 2023

On July - July 13, 2023

Caribou Biosciences, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - July 13, 2023

Caribou Biosciences Reports Positive Clinical Data From Dose Escalation Of Cb-010 Antler Phase 1 Trial In R/R B-Nhl - July 13, 2023

Statement of acquisition of beneficial ownership by individuals - July 10, 2023

Caribou Biosciences Announces $25 Million Equity Investment From Pfizer - July 6, 2023

Submission of Matters to a Vote of Security - June 16, 2023

Caribou Biosciences, Inc.'s President and CEO just picked up 10,000 shares - June 9, 2023

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - April 28, 2023

Caribou Biosciences, Inc. releases salary data. CEO sees compensation fall -86% - April 28, 2023

Caribou Biosciences Announces Fda Granted Fast Track Designation To Cb-011, An Allogeneic Car-T Cell Therapy For Relapsed Or Refractory Multiple Myeloma - April 4, 2023

Caribou Biosciences Initiates Dose Expansion Portion Of Cb-010 Antler Phase 1 Trial In - March 29, 2023

Caribou Biosciences Announces Dosing Of First Patient In The Cammouflage Phase 1 Trial Of Cb-011, An Allogeneic Anti-Bcma Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myelom - March 29, 2023

On March - March 24, 2023

Caribou Biosciences, Inc.'s President and CEO just picked up 10,000 shares - March 22, 2023

Caribou Biosciences, Inc. Just Filed Its Annual Report: Net Loss Per Share B... - March 9, 2023

Securities to be offered to employees in employee benefit plans - March 9, 2023

Caribou Biosciences Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update - March 9, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s Chief Medical Officer was just granted 131,000 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s Chief Scientific Officer was just granted 131,000 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s President and CEO was just granted 510,500 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s Chief Business Officer was just granted 131,000 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s Chief Legal Officer was just granted 131,000 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc.'s Chief Financial Officer was just granted 131,000 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Caribou Biosciences, Inc. director was just granted 21,500 options - Feb. 23, 2023

Statement of acquisition of beneficial ownership by individuals - Feb. 9, 2023

Statement of acquisition of beneficial ownership by individuals - Feb. 3, 2023

BlackRock, Inc. just provided an update on share ownership of Caribou Biosciences, Inc. - Feb. 3, 2023

Caribou Biosciences, Inc.'s Chief Medical Officer just disposed of 5,627 shares - Jan. 20, 2023

Departure of Directors or Certain - Dec. 16, 2022

Caribou Biosciences Reports Cb-010 Antler Phase 1 Trial Progress - Dec. 12, 2022

Caribou Biosciences, Inc.'s Chief Scientific Officer just picked up 21,401 shares - Dec. 2, 2022

Caribou Biosciences Announces The Fda Granted Regenerative Medicine Advanced Therapy (Rmat) And Fast Track Designations To Cb-010, An Allogeneic Anti-Cd19 Car-T Cell Therapy - Nov. 29, 2022

Caribou Biosciences Announces Fda Clearance Of Ind Application For Cb-011, An Allogeneic Anti-Bcma Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma - Nov. 21, 2022

Caribou Biosciences, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareTh... - Nov. 8, 2022

Caribou Biosciences Reports Third Quarter 2022 Financial Results And Provides Business Update - Nov. 8, 2022

Caribou Biosciences To Present Antler Trial-In-Progress Poster At The - Nov. 3, 2022

Caribou Biosciences Presents Case Report On Long-Term Follow Up Of First Patient Dosed In Phase 1 Antler Trial At The Lymphoma, Leukemia, & Myeloma Congress 2022 - Oct. 18, 2022

Caribou Biosciences, Inc.'s VP of Finance and Controller just disposed of 4,322 shares - Oct. 7, 2022

Submission of Matters to a Vote of Security - Sept. 22, 2022

Caribou Biosciences, Inc.'s Chief Legal Officer just picked up 27,595 shares - Sept. 16, 2022

Caribou Biosciences, Inc.'s Chief Scientific Officer just cashed-in 43,248 options - Aug. 26, 2022

Caribou Biosciences, Inc.'s Chief Business Officer was just granted 70,000 options - Aug. 24, 2022

Caribou Biosciences, Inc.'s VP of Finance and Controller just picked up 4,848 shares - Aug. 24, 2022

Notice of Effectiveness - Aug. 16, 2022

Entry into a Material Definitive - Aug. 12, 2022

Caribou Biosciences: Soliciting Material Pursuant To §240. 14A-12 CARIBOU BIOSCIENCES, INC. - Aug. 11, 2022

Caribou Biosciences, Inc. releases salary data. CEO sees compensation rise 841% - Aug. 11, 2022

Departure of Directors or Certain - July 18, 2022

On July - July 15, 2022

Caribou Biosciences Reports Positive Additional Data From Cb-010 Allogeneic Car-T Cell Therapy Phase 1 Antler Trial At The European Hematology Association (Eha) 2022 Hybrid Congress - June 10, 2022

Caribou Biosciences Announces Webcast Conference Call To Highlight Initial Cb-010 Antler Phase 1 Data Presentation At Eha On June 10, 2022 - June 1, 2022

Statement of acquisition of beneficial ownership by individuals - June 1, 2022

Caribou Biosciences, Inc. director was just granted 44,000 options - May 18, 2022

Caribou Biosciences, Inc.'s Chief Scientific Officer just picked up 74,420 shares - May 17, 2022

Caribou Biosciences Announces Positive Initial Data For Cb-010 Anti-Cd19 Allogeneic CAR-T Cell Therapy - May 12, 2022

Caribou Biosciences Announces Appointment Of David Johnson - May 11, 2022

Caribou Biosciences, Inc.'s President and CEO just picked up 10,000 shares - May 10, 2022

Caribou Biosciences, Inc.'s President and CEO just picked up 10,000 shares - May 10, 2022

Caribou Biosciences, Inc. Just Filed Its Quarterly Report: 14. Net Loss Per Sha... - May 9, 2022

Caribou Biosciences Reports First Quarter 2022 Financial Results And Provides Business Updates - May 9, 2022

Caribou Biosciences, Inc.'s VP of Finance and Controller just picked up 2,274 shares - May 6, 2022

Caribou Biosciences To Share Cb-010 Initial Clinical Data At The Upcoming - April 25, 2022

Securities to be offered to employees in employee benefit plans - March 21, 2022

Caribou Biosciences Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Update - March 21, 2022

Caribou Biosciences, Inc. Just Filed Its Annual Report: Net Loss Per Share B... - March 21, 2022

Caribou Biosciences, Inc.'s VP of Finance and Controller just picked up 2,274 shares - March 17, 2022

Caribou Biosciences, Inc.'s Chief Scientific Officer just picked up 10,720 shares - March 7, 2022

Brian D. Grossman just provided an update on share ownership of Caribou Biosciences, Inc. - Feb. 14, 2022

Mark C. Wehrly just provided an update on share ownership of Caribou Biosciences, Inc. - Feb. 11, 2022

Caribou Biosciences, Inc.'s President and CEO just cashed-in 3,349,395 options - Feb. 9, 2022

Caribou Biosciences, Inc.'s Chief Financial Officer just picked up 24,336 shares - Feb. 8, 2022

Felix Adler just provided an update on activist position in Caribou Biosciences, Inc. - Feb. 4, 2022

Caribou Biosciences, Inc.'s President and CEO just picked up 10,000 shares - Jan. 27, 2022

Caribou Biosciences, Inc.'s Chief Medical Officer just picked up 60,000 shares - Jan. 25, 2022

Caribou Biosciences, Inc.'s Chief Medical Officer just declared owning 5,000 shares of Caribou Biosciences, Inc. - Jan. 24, 2022

Entry into a Material Definitive - Jan. 19, 2022

Caribou Biosciences Appoints Syed Rizvi, M.D., As Chief Medical Officer - Jan. 18, 2022

Caribou Biosciences, Inc.'s VP of Finance and Controller just picked up 7,387 shares - Jan. 12, 2022

Caribou Biosciences, Inc. director was just granted 13,060 options - Dec. 22, 2021

Caribou Biosciences, Inc.'s President and CEO was just granted 411,000 options - Dec. 21, 2021

Caribou Biosciences, Inc. director was just granted 13,750 options - Dec. 21, 2021

Caribou Biosciences, Inc. director was just granted 27,500 options - Dec. 21, 2021